for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cyclacel Pharmaceuticals Inc

CYCC.OQ

Latest Trade

0.37USD

Change

0.00(+0.51%)

Volume

8,676

Today's Range

0.37

 - 

0.39

52 Week Range

0.28

 - 

1.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.37
Open
0.39
Volume
8,676
3M AVG Volume
1.49
Today's High
0.39
Today's Low
0.37
52 Week High
1.70
52 Week Low
0.28
Shares Out (MIL)
17.20
Market Cap (MIL)
6.40
Forward P/E
-0.60
Dividend (Yield %)
--

Latest Developments

More

Cyclacel Pharmaceuticals Announces Qtrly Loss Per Share $0.11

Cyclacel Pharmaceuticals Inc Files For Mixed Shelf Of Upto $100 Million

Cyclacel Pharmaceuticals Reports Qtrly Net Loss Per Share $0.12

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Industry

Biotechnology & Drugs

Contact Info

200 Connell Dr Ste 1500

+1.908.5177330

http://www.cyclacel.com/

Executive Leadership

David Charles U'Prichard

Independent Chairman of the Board

Spiro George Rombotis

President, Chief Executive Officer, Director

Christopher S. Henney

Independent Vice Chairman of the Board

Paul McBarron

Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director

Judy H. Chiao

Vice President - Clinical Development and Regulatory Affairs

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.500

2018

-0.620

2019(E)

-0.620
Price To Earnings (TTM)
--
Price To Sales (TTM)
42.69
Price To Book (MRQ)
0.41
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-43.20
Return on Equity (TTM)
-36.55

Latest News

Latest News

BRIEF-Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln

* CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Cyclacel Pharma Projects Cash Resources To Fund Currently Planned Programs Through End Of 2019

* CYCLACEL PHARMACEUTICALS INC - CO PROJECTS CASH RESOURCES TO FUND CURRENTLY PLANNED PROGRAMS THROUGH END OF 2019 Source text for Eikon: Further company coverage:

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

BRIEF-Cyclacel Pharmaceuticals Q2 loss per share $0.50

* Cyclacel Pharmaceuticals reports second quarter 2017 financial results

BRIEF-Intra-Cellular Therapies reports Q2 loss per share $0.41

* Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update

BRIEF-Cyclacel announces selection of recommended phase 2 dose for CYC065

* Cyclacel announces selection of recommended phase 2 dose for CYC065 and evidence of durable target engagement and MCL-1 biomarker suppression Source text for Eikon: Further company coverage:

BRIEF-Cyclacel announces pricing of $13.2 mln underwritten public offering

* Cyclacel announces pricing of $13.2 million underwritten public offering

BRIEF-Cyclacel Pharmaceuticals says approved extension of employment agreements with CEO and CFO

* Cyclacel pharmaceuticals - compensation and organization development committee approved extension of employment agreements with ceo spiro rombotis, cfo paul mcbarron

BRIEF-Cyclacel Pharma files for potential offering of up to $15 mln

* Cyclacel pharmaceuticals inc- files for potential offering of up to $15 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Cyclacel Pharmaceuticals Q1 loss per share $0.38

* Cyclacel pharmaceuticals reports first quarter 2017 financial results

BRIEF-Intra-Cellular therapies reports Q1 loss per share $0.62

* Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies provides corporate update on schizophrenia program

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

BRIEF-Cyclacel Pharmaceuticals reports Q4 and full year 2016 financial results

* Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel Pharmaceuticals Inc said its experimental drug failed in a late-stage study on patients aged 70 years or more with newly diagnosed acute myeloid leukemia.

BRIEF-Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia

* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up